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Abstract
Introduction—Because small cell lung carcinomas (SCLC) are seldom resected, human 
materials for study are limited. Thus, genetically engineered mouse models (GEMMs) for SCLC 
and other high-grade lung neuroendocrine (NE) carcinomas are crucial for translational research.
Methods—The pathologies of five GEMMs were studied in detail and consensus diagnoses 
reached by four lung cancer pathology experts. Hematoxylin and Eosin and immunostained slides 
of over 100 mice were obtained from the originating and other laboratories and digitalized. The 
GEMMs included the original Rb/p53 double knockout (Berns laboratory) and triple knockouts 
from the Sage, MacPherson and Jacks laboratories (double knockout model plus loss of p130 
(Sage laboratory) or loss of Pten (MacPherson and Jacks laboratories). In addition, a GEMM with 
constitutive co-expression of SV40 large T antigen (Tag) and Ascl1 under the Scgb1a1 promoter 
from the Linnoila laboratory was included.
Results—The lung tumors in all of the models had common as well as distinct pathological 
features. All three conditional knockout models resulted in multiple pulmonary tumors arising 
mainly from the central compartment (large bronchi) with foci of in situ carcinoma and NE cell 
hyperplasia. They consisted of inter- and intra-tumor mixtures of SCLC and large cell NE cell 
carcinoma (LCNEC) in varying proportions. Occasional adeno- or large cell carcinomas were also 
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seen. Extensive vascular and lymphatic invasion and metastases to the mediastinum and liver were 
noted, mainly of SCLC histology. In the Rb/p53/Pten triple knockout model from the MacPherson 
and Jacks laboratories and in the constitutive SV40/Tag model many peripherally arising NSCLC 
tumors having varying degrees of NE marker expression were present (NSCLC-NE tumors). The 
resultant histological phenotypes were influenced by the introduction of specific genetic 
alterations, by inactivation of one or both alleles of specific genes, by time from Cre activation 
and by targeting of lung cells or NE cell subpopulations.
Conclusion—The five GEMM models studied are representative for the entire spectrum of 
human high-grade NE carcinomas and are also useful for the study of multistage pathogenesis and 
the metastatic properties of these tumors. They represent one of the most advanced forms of 
currently available GEMM models for the study of human cancer.
Introduction
For a number of clinical, therapeutic, pathological and biological reasons, small cell 
carcinoma of the lung (SCLC) is regarded as an entity distinct from the more common non-
small cell carcinomas (NSCLC).1, 2 SCLC is neuroendocrine (NE) tumor and it is the most 
common and aggressive subtype within the spectrum of NE lung tumors. NE tumors of the 
lung are a distinct subset of tumors, which share morphologic, ultrastructural, 
immunohistochemical and molecular characteristics although these tumors are classified into 
different morphologic categories within the WHO classification.3, 4 Pulmonary NE tumors 
may be divided into two categories: a) high-grade NE carcinomas consisting of SCLC and 
large cell NE carcinomas (LCNEC) and b) low grade NE tumors consisting of the carcinoid 
tumors, typical and atypical.5 High-grade NE lung carcinomas are characterized by strong 
association with tobacco usage, high mitotic and proliferative indices, initial response to 
chemotherapy, widespread metastases, almost universal inactivation of the TP53 and RB1 
genes, and other characteristic molecular alterations. Whether all NE tumors arise from 
respiratory tract NE cells, from less differentiated multipotent cells, or cells committed to 
other lineages is disputed.6, 7 While all pulmonary NE tumors may originate from the same 
pulmonary precursor cells, precursor lesions have not been convincingly identified for high-
grade NE carcinomas.8 Pulmonary neuroendocrine cell hyperplasia, has been observed in 
association with carcinoids, but no clear association is recognized with other lung cancers 
including SCLC.9, 10 Multiple potential targets for individualized therapy have been 
identified in SCLC cells.11, 12 However, despite several clinical trials, effective targeted 
therapies for SCLC are not currently available.13 Because curative intent resections are 
seldom performed for SCLC, there is a paucity of tumor materials for the performance of 
translational research. Biological and preclinical studies of SCLC largely depend on the 
availability of modest sized banks of human cell lines.14 Thus, the introduction of a 
genetically engineered mouse model15 resulting from the somatic inactivation of the Tp53 
and Rb1 genes represented an important step.2 These mice developed aggressive NE lung 
cancers, termed SCLC, which gave rise to extrapulmonary metastases and required bi-allelic 
inactivation of both genes. A reported preinvasive feature was the presence of hyperplastic 
and dysplastic foci and nodules, particularly in the larger airways. However, the latent 
period for tumor formation was relatively long (7-12 months). Later, Schaffer et al. reported 
that the additional conditional loss of p130, a cell cycle inhibitor in the Rb1 gene family, 
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shortened the latent time in the Rb/p53/p130 triple-knockout mouse model.16 The 
histopathology of these metastatic mouse tumors was also reported to closely resemble 
human SCLC. More recently, another triple knockout model (with the additional conditional 
inactivation of the Pten gene in the Rb/Tp53 floxed model) has been described.17 
Heterogeneous inactivation of the Pten gene resulted in SCLC like tumors after a shorter 
latent period, but also in adenocarcinomas with varying degrees of NE cell differentiation 
(NSCLC-NE tumors). Homozygous inactivation of Pten resulted in NSCLC carcinomas 
with varying degrees of NE cell differentiation. Another variation of the Rb/p53/Pten triple 
knockout model has been described by McFadden et al.18 A further complicating factor is 
that the classification of NE carcinomas is that some otherwise typical appearing human 
NSCLC tumors, usually adenocarcinomas, express much or all of the neuroendocrine cell 
program - so called NSCLC with NE features (NSCLC-NE). These tumors remain largely 
unstudied with differing views on incidence and therapeutic options.19-24 However, 
microarray expression profiling identifies a subgroup of human lung adenocarcinomas that 
express NE cell features, confirming the presence of NSCLC-NE as a subset of 
NSCLC.25, 26 Congress passed into law the Recalcitrant Cancer Research Act in 2013, 
calling on the National Cancer Institute (NCI) “to develop scientific frameworks that will 
help provide the strategic direction and guidance needed to make true progress against 
recalcitrant cancers”, defined as those with a five-year relative survival rate below 50 
percent. Following a workshop held in Bethesda, MD in 2013, a report on “The Scientific 
Framework for Small Cell Lung Cancer” was issued (http://www.lungcanceralliance.org/
News/SCLC%20Congressional%20Response%206-30-14%20FINAL%20with
%20appendices.pdf). One of the priorities identified in the report was the development of 
better models for SCLC including GEMMs. As described below, five GEMM models for 
NE lung carcinomas have been described, and more are under development. However, 
descriptions of the detailed pathology of most of these models are lacking. Recently we 
(AFG and EB) had the opportunity to review the pathology of the GEMMs propagated at 
our respective institutions (UT Southwestern Medical Center and Institut Albert Bonniot). 
We found similarities and differences between the histological appearances of the mouse 
models and human SCLC, and also between the different mouse models. We undertook 
detailed analyses of the pathology of the currently described NE mouse models and their 
preinvasive changes, and invited the senior initiators of the models (AB, JS, DM, IL and TJ) 
to collaborate with us and submit pathological materials of the GEMMs from their 
respective laboratories for pathological examination. The primary purpose of the study was 
to determine the suitability of the GEMMs as models for the study of human SCLC and 
other neuroendocrine carcinomas.
Materials and Methods
GEMMs
Five GEMMs for NE lung tumors were obtained from seven independent laboratories -the 
originating laboratory, as well as from multiple sources for some models (Table 1). These 
models have been described previously, and details are available from the cited references. 
For the conditional models, tumors were initiated by adenoviral delivery of Cre.27
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Pathology examination
Tissues from over 120 mice were examined, over 80 from the Rb/p53 double knockout 
model, and five to 15 each from the other four models. Mice were sacrificed either when 
symptomatic or at defined intervals after Cre activation. Lungs and other tissues (liver, 
mediastinum, regional lymph nodes) were fixed in neutral buffered formalin, paraffin 
embedded and 5μ H. & E. stained sections prepared. For representative cases immunostains 
for NE cell markers (Ascl1, ChgA, Cgrp and Syn) were performed on corresponding 
sections. NKX2-1 staining, a marker for both adenocarcinoma and NE lung cancers, was 
available for some tumors. Entire slides were digitally scanned at high (40X) resolution 
using the NanoZoomer 2.0 HT Digital Pathology System (Hamamatsu Photonics, 
Hamamatsu City, JP) and examined using the manufacturer's software. One pathologist 
(AFG) examined all of the scanned images in detail and captured multiple representative 
images. These were distributed to the other three pathologists (EB, WDT and IL) and 
consensus diagnoses were reached about each model.
Pathologic criteria for diagnosis
For diagnosis, we used standard definitions as stated by the World Health Organization 
(WHO) classification of tumors of the lung:3, 4 1) Small cell carcinoma (SCLC): A NE 
carcinoma having cells of a small size, with scant cytoplasm, nuclei with finely granular 
nuclear chromatin, inconspicuous nucleoli, high mitotic rate, frequent necrosis often 
covering large zones (“geographic necrosis”). Another criterion we used was the presence of 
the Azzopardi effect in ischemic areas, a feature present in about 30% of human SCLC 
tumors.28 This feature, highly characteristic of SCLC, represents deposition of basophilic 
DNA-containing material on blood vessel walls resulting from release of nucleic acids in 
large amounts from degenerating cellular neoplastic tissues. 2) Large cell neuroendocrine 
carcinoma (LCNEC): A tumor with a neuroendocrine morphology (organoid nesting, 
palisading, rosettes, trabeculae), high mitotic rate, frequent area of necrosis, often 
geographic, cytologic features of a NSCLC (large cell size, low nuclear to cytoplasmic ratio, 
vesicular, coarse or fine chromatin, and/or frequent nucleoli. Some tumors have fine nuclear 
chromatin and lack nucleoli, but qualify as NSCLC because of large cell size and abundant 
cytoplasm.10 3) Non small cell carcinoma with neuroendocrine features (NSCLC-NE). 
These are defined as otherwise typical NSCLC tumors (often adenocarcinomas or large cell 
carcinomas) expressing one or more NE cell properties, but lacking the typical 
morphological features of NE carcinomas (see above). Demonstration of NE cell properties 
by positive immunostaining for one or more NE markers (other than neuron specific 
enolase) and/or presence of cytoplasmic NE granules by electron microscopy. These tumors 
remain largely unstudied with differing views on incidence and therapeutic options.22-24, 29
Results
A brief overview of the major pathological changes observed in the various GEMMs is 
presented in Table 2.
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Pathology of Rb/p53 Double knockout and Rb/p53/p130 Triple knockout GEMMs
These represent the original Rb/p53 double knockout established in the Berns laboratory in 
2003. In an effort to shorten the lengthy latency time, the Sage laboratory created the first of 
the triple knockouts in 2010. Both of these models gave rise to central tumors arising from 
non-invasive lesions originating in the large bronchi, although occasional tumors appear to 
have arisen in the peripheral lung from respiratory bronchioles or alveolar ducts. Most of the 
preinvasive lesions consisted of cells having similar morphology to the accompanying 
invasive component (see below), and were regarded as carcinoma in situ lesions. The 
distinction between SCLC (Fig.1-2) and LCNEC (Fig. 3) was more difficult in the in situ 
lesions, especially small ones. Neuroepithelial bodies and foci of NE cell hyperplasia 
protruding into the lumen were occasionally present although most appeared independent of 
the in situ and invasive components. The Rb/p53 double knockout was the most abundant 
source of materials for the present study, with over 80 affected mice available from all five 
participating laboratories. Irrespective of the laboratory source, the pathology of the 
resultant mouse tumors was uniform and virtually identical. Mice were sacrificed 10-15 
months after Cre activation. Mice sacrificed early had mainly in situ lesions, while mice 
sacrificed later had multiple tumors occupying up to 60% of the lung volume, with vascular 
and peribronchial invasion and perivascular and peribronchial intralymphatic metastases 
(Fig. 2). They were accompanied by extensive mediastinal spread and lymph node and 
hepatic metastases. In some cases extensive mediastinal involvement was noted with only 
modest intrapulmonary tumor burdens. The histology of most of the metastases consisted 
largely or solely of the SCLC cell component (see below). The majority of the tumor cells in 
the Rb/p53 double knockout model were very similar to those of human SCLC. The cells 
formed sheets of small cells having high mitotic rates, scant poorly defined cytoplasm, 
nuclei with the presence of small (but distinct) nucleoli, areas of geographic necrosis and 
foci of Azzorpardi effect. Minor differences compared to human SCLC were the lack of 
small “salt and pepper” like chromatin granules and small but distinct nucleoli in most of the 
tumor cells. The granules in this GEMM were somewhat larger and more distinct, with some 
surrounding perinucleolar clearing. A feature occupying about 10% of the tumors was the 
presence of foci compatible with LCNEC – the cells were larger, more clearly outlined, with 
larger nuclei and sometimes with prominent nucleoli. Features indicative of NE tumors 
included organoid nests, palisading, trabeculation and rosette formation. The LCNEC foci 
occurred both as distinct tumor nodules, as well as being interspersed with the more typical 
SCLC component. In the mixed foci, transition zones between the two histological types 
were observed. Of interest, the regions with Azzopardi effect were limited to the SCLC 
areas. About 10% of the tumors resembled NSCLC, especially adenocarcinoma or large cell 
carcinoma and they lacked expression of NE cell markers. Metastases of the NSCLC tumors 
were not observed.
The Triple Rb/p53/p130 knockout tumors from the Sage and Johnson laboratories had a 
shorter latent time and the mice were sacrificed electively 5 months post Cre activation or at 
later times when showing signs of distress. Most mice had centrally arising NE tumors, 
although occasional NSCLC tumors were noted. Mice sacrificed early had mainly in situ 
lesions, while mice sacrificed later had multiple tumors occupying up to 60% of the lung 
volume, with vascular and lymphatic invasion and perivascular and peribronchial 
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intralymphatic metastases. In contrast to the Rb/p53 double knockout model, the Rb/p53/
p130 triple knockout tumors had a predominantly LCNEC component when the mice were 
sacrificed early, but the SCLC component became more prominent when sacrificed at later 
time points. In mixed histology tumors, the Azzorpardi effects were limited to the SCLC 
component. In some of these mixed tumors there was not a clear distinction between the two 
NE cell components, but a gradual transition from one to the other. However, lymphatic, 
vascular and hepatic metastases had a predominantly SCLC histology, suggesting that this 
component had a longer latent time but also had a greater metastatic potential. As with the 
Rb/p53 double knockout model, occasional foci of NE cell hyperplasia or neuroepithelial 
bodies (NEBs) were noted in bronchi, although there was no obvious relationship to the in 
situ or invasive tumors.
Pathology of Rb/p53/Pten Triple knockoutPten GEMMs
The pathology of the tumors, induced by the addition of Pten knockout (either Ptenlox/lox or 
Ptenlox/+)17 to the original Rb/p53 double knockout model developed in the Berns lab, was 
more complex than any of the other models included in this study. In the MacPherson lab, 
all lung cells were targeted using intratracheal infection with Ad-CMV-Cre and two 
genotypes were studied – with either one or both Pten alleles inactivated by Cre. Mice were 
sacrificed when symptomatic. Tumors developed much faster after adenoviral Cre delivery 
with rapid mortality, especially for the Rb/p53/Ptenlox/lox mice usually 4-5 months post Cre 
and gross metastases were not noted. In the Rb/p53/Ptenlox/+ model, dominant tumors 
emerged mostly from mice that got sick 7-9 months post Cre, and about two thirds had liver 
metastases. Both of the Rb/p53/Pten subtype mice had multiple tumors apparently arising 
both from the central and peripheral airways. The tumors consisted of two major subtypes – 
those resembling SCLC and those with NSCLC features, particularly adenocarcinoma. 
However the SCLC-like component was more prominent in the Ptenlox/+ mice. The 
cytological resemblance to human SCLC was not as striking as the double Rb/p53 knockout 
(Berns) model with many cells having distinct small nucleoli and defined outer cell borders. 
We refer to these cells as SCLC-like. The NSCLC component consisted of adenocarcinomas 
with acinar and palisading features and occasional mucin-like secretory material, both intra- 
and extra-cellular. Multiple large linear, multilayered regions of in situ carcinoma were 
noted. These consisted largely of the SCLC cells, although occasionally of the NSCLC 
component or admixtures of the two. By contrast, the in situ lesions in the Rb/p53 double 
and Rb/p53/p130 triple knockout models consisted almost entirely of the NE cell 
component, and were smaller and more globular in shape. Foci of hyperplastic basal cells or 
NEBs were rarely identified. Metastases to the mediastinal nodes and liver were frequent in 
the Rb/p53/Ptenlox/+ model, and the SCLC-like cell component dominated in the metastases. 
Immunostaining of both morphologic phenotypes showed considerable heterogeneity, with 
some foci of both SCLC-like and NSCLC staining uniformly, while others were negative or 
were variable in intensity and distribution. This heterogeneity extended to in situ and 
metastatic lesions.
A similar Rb/p53/Pten triple knockout model was developed in the Jacks laboratory, but 
using adenoviral Cre vectors driven by the CGRP promoter and targeting NE lung cells 
specifically. Both Pten alleles were inactivated in this model. These mice developed tumors 
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rapidly with frequent liver metastases but the tumor histologies showed somewhat different 
features than the model from the MacPherson laboratory. Mild-modest NE cell hyperplasia 
and NEBs were present in the large bronchi. While most of the in situ lesions were LCNEC, 
and occasionally SCLC, three types of invasive cancers were noted: About 60% were 
LCNEC, 20% SCLC and 20% NSCLC. Heterogeneous expression of CGRP expression was 
present in all three forms of invasive cancers, as well as in the in situ lesions. However the 
metastases to peribronchial and perivascular lymphatics and to the liver were almost all 
SCLC.
Pathology of CC10-SV40Tag-Ascl1 model GEMM
In this model there is constitutive co-expression of SV40 large T antigen (Tag) and Ascl1 
under the Scgb1a1 (also known as CC10) promoter.30-32 At a relatively young age (2-4 
months) mice develop extensive acinar adenocarcinomas, mainly peripheral, but with some 
arising in larger bronchi (Fig. 5). In addition to the adenocarcinomas, foci of NE cell 
hyperplasia that appeared linear along the epithelium were present in the large bronchi. 
While the foci of NE cell hyperplasia expressed the NE cell markers (Ascl1, Cgrp and Syn) 
strongly and uniformly, expression in the adenocarcinomas was focal, weaker and 
heterogeneous. Nkx2.1 was also expressed in both the NE cell hyperplasias and in the 
adenocarcinomas.
Discussion
As appropriate GEMMs are a key component for the understanding of SCLC and other 
high-grade NE lung carcinomas, we undertook a detailed pathological review of the multiple 
mouse models currently available to us. We obtained these models both from the originating 
laboratories, as well as from other laboratories that had replicated the models. We are aware 
that several other GEMMs for NE lung cancers are currently under development or study. 
However, as these have not been described in the literature, we chose not to include them in 
this study even though, in some instances, the originators were willing to share them with 
us.
Early GEMM models were created by ectopic transgene expression under the control of 
lung-specific promoters.33, 34 More advanced GEMMs allow for inducible, tissue-specific 
expression of oncogenes as well as conditional, tissue-specific deletion of tumor 
suppressors. We included in our study one early model, described more than a decade ago 
from the Linnoila laboratory, as it represented a model for the poorly understood and studied 
NSCLC-NE. In this model, lung tumors are generated by constitutive expression of Ascl1 in 
combination with SV40 Tag under the secretoglobin1a1 gene promoter. The other four 
models were more advanced models that utilized or modified the original double knockout 
concept from the Berns laboratory. As Berns postulated, because biallelic inactivation of 
TP53 and RB1 genes are near universal in human SCLC, knocking out these two genes in 
mouse lung epithelial cells would result in SCLC like tumors. However, in this GEMM, the 
latent period for tumor development was long (about 12 months). Human SCLC tumors 
almost always occur in patients having lengthy and extensive smoke exposure histories, and 
are accompanied by numerous molecular changes.11, 12, 35 By contrast, GEMMs for NE 
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lung cancers are not exposed to tobacco carcinogens, and require spontaneous development 
of further genetic changes for tumor development including frequent amplification of the 
Nfib and L-Myc genes.36, 37 The secondary changes in the GEMM model for SCLC from the 
Jacks lab included alterations in DNA copy number and complex genomic rearrangements 
but a relatively low somatic point mutation frequency in the absence of tobacco 
mutagens.17,18 Alterations targeting the tumor suppressor Pten occurred in the majority of 
murine SCLC studied. The relatively lengthy time required for these secondary changes to 
occur results in long latent periods for tumor development. The Sage, MacPherson and Jacks 
laboratories, in efforts to shorten the latent time, utilized triple knockout GEMMs, 
modifying the original Rb/p53 double knockout model with the additional inactivation of a 
third tumor suppressor gene. Further refinements include Cre activation in all exposed lung 
cells or promoter activation in specific lineage subpopulations such as pulmonary NE cells. 
A further confounding factor is the inactivation of one or both alleles of more of the utilized 
genes. As described herein, these additional alterations affected the pathological features of 
the resulting tumors.
The five models studied shared some pathological features, although there were also 
individual features characterizing each GEMM. Most tumors arising in the Rb/p53 Berns 
laboratory double knockout model closely resembled human SCLC, although some minor 
cytological differences were noted. A minor subpopulation of LCNEC was present in most 
mice, either as individual foci or admixed with the SCLC foci, with transition areas. About 
10% of the tumors appeared to be NSCLC, especially adenocarcinoma, and lacked NE cell 
differentiation. The original report from the Berns lab indicated that biallelic inactivation of 
the Rb1 gene was essential for SCLC tumors in the double knockout model, and that 
NSCLC may arise in the absence of biallelic inactivation.15, 38 These NSCLC tumors lacked 
NE cell differentiation. Another interesting feature was the presence of multiple, often large, 
nodular and protruding foci of in situ NE cell carcinoma. Occasional foci of basally located 
NE cell hyperplasia or increased numbers of NEBs were noted, usually distinct from the 
carcinoma in situ foci. NEBs represent basally located focal collections of NE cells in the 
respiratory epithelium.39 As premalignant or preinvasive lesions are very seldom recognized 
in human SCLC tumors, the GEMMs provide unique models to study the multistage 
pathogenesis of these tumors. We, and others, have suggested that lung carcinomas may 
arise from the central or peripheral compartments of the lung, with most squamous cell and 
SCLC carcinomas arising from the former, and most adenocarcinomas arising from the 
latter.40 The in situ findings from the GEMMs confirm the central origin of most SCLC and 
LCNEC tumors. This is consistent with the findings of Sutherland et al that most SCLC 
tumors arise from centrally located NE cells while occasional tumors may also arise from 
peripherally located SPC positive cells.41
The Rb/p53/p130 triple knockout model from the Sage laboratory had LCNEC as the most 
prominent of the in situ and early invasive lesions, with a SCLC component becoming more 
prominent when mice were sacrificed at a later time point. However SCLC formed the 
majority of the metastatic lesions. There appeared to be plasticity between the two 
components, with individual tumors expressing both phenotypes with transitional zones 
where the demarcation was not clear. Thus addition of p130 knockout to the original Berns 
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double knockout model resulted in shorter latent periods, but was accompanied by 
alterations of the major tumor cell phenotype that altered with time to sacrifice. At all time 
points, SCLC was the predominant component of metastases to lymph node, mediastinum or 
liver. These observations suggest the close relationship and inter-relationship of SCLC and 
LCNEC. While the SCLC component was slower to develop, perhaps because more 
secondary genetic changes were needed for its development, it was the predominant 
phenotype present in metastases of all the GEMM models studied.
The Rb/p53/Pten triple from the MacPherson laboratory (with mono- or biallelic inactivation 
of Pten added to the original double knockout model)17 had the most complex and varied 
pathology of the models studied. The resultant tumors had two major phenotypes: Centrally 
arising SCLC tumors and multiple peripherally arising NSCLC, usually adenocarcinomas, 
with intra- and inter-tumor heterogeneity of NE marker expression. While the pathological 
description in the original report of this model suggested major differences between the 
mono- and biallelic Pten inactivated tumors, we interpret them as being part of a spectrum, 
with the SCLC-like component being dominant in the monoallelic (heterozygous) tumors 
and the NSCLC-NE tumors dominant in the biallelic model. One possible explanation is that 
the short latent period for the development of the extensive NSCLC component in the 
biallelic model resulted in death of the mice before the SCLC-like component had time to 
fully develop.
The triple Rb/p53/Pten triple knockout model from the MacPherson laboratory targeted all 
available lung cells using Ad-CMV-Cre while the similar model from the Jacks lab targeted 
NE cells using Ad-CGRP-Cre. Perhaps as a result, the tumors from the Jacks laboratory 
demonstrated a mixture of LCNEC, SCLC and NSCLC, while the equivalent model from 
the MacPherson laboratory had NSCLC with varying expression of NE features as a 
prominent component.
While the Rb/p53/Pten triple knockout model resulted in NSCLC-NE tumors, the 
constitutive SV40/Ascl1 model from the Linnoila laboratory also induced NSCLC-NE 
tumors, but without the prominent SCLC-like component seen in the Rb/p53/Ptenlox/+ 
model. In both SV40/Ascl1 and Rb/p53/Ptenlox/lox models the NSCLC-NE tumors 
demonstrated considerable intra and inter-tumor heterogeneity of NE cell markers. NE 
marker expression was less intense than in SCLC or LCNEC components of the Rb/p53 
double knockout or Rb/p53/p130 triple knockout models. It is of interest to point out the 
contrasting features of the GEMMs for the NE carcinoma models as summarized in this 
report, and those of the many GEMM models for NSCLC (Table 3). Most NSCLC GEMMs 
arise peripherally and are characterized by intense hyperplastic lesions and adenoma 
formation, with foci of true invasive carcinoma and metastases occurring occasionally and 
relatively late in the disease process.42, 43 By contrast, the GEMMs for NE carcinomas have 
relatively long latent periods, with the exception of the SV40 driven constitutive model from 
Linnoila laboratory, arise from the central compartment, hyperplastic foci are rare, 
adenomas are not seen, and invasive carcinomas and metastatic lesions are frequent.42-44
Metastatic lesions were present in all the models for which metastatic lesions were available 
for examination. These were most frequent and extensive in the Berns laboratory model, 
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where mice were sacrificed late, often when symptomatic. The extent and pattern of 
metastatic spread, sometimes in the presence of modest intrapulmonary tumor load, were 
highly reminiscent of human SCLC – perivascular and peribronchial spread, large 
mediastinal node involvement, frequent and multiple liver metastases. As previously 
mentioned, most metastases in all the models had SCLC cells as the principal or sole 
component, whether or not this was the dominant tumor cell component in the 
intrapulmonary tumors.
GEMMs for NE carcinomas of the lung present a unique set of models for the study of an 
important human disease for which human tissues are seldom available. The pathological 
features of the four GEMMs that form the basis of this report all share some features, but 
also have individual characteristics. They represent the entire spectrum of high-grade NE 
carcinomas of the lung including LCNEC. While the original double knockout model from 
the Berns laboratory showed the greatest resemblance to human SCLC, many tumors also 
demonstrated features of LCNEC. These two NE cell components often showed mixed 
patterns in individual tumors, with transitional features from one to the other. These findings 
indicate that the distinction between the two main forms of high-grade NE lung carcinomas 
is not absolute but relative, and that transitions between them may occur. NSCLC tumors, 
with or without expression of NE cell markers were a prominent feature of the Rb/p53/Pten 
triple knockout from the MacPherson laboratory and the constitutive SV40/Ascl1 model 
from the Linnoila laboratory.
These models offer a spectrum of pathological phenotypes ranging from SCLC, LCNEC, 
NSCLC and the poorly understood NSCLC-NE tumors. In most cases, the widely metastatic 
pattern of the conditional models closely resembles the pattern of spread of human SCLC. It 
appears that multiple factors can influence the resultant tumor phenotypes including 
introduced genetic changes, targeting of niche subpopulations such as NE cells, mono- or 
biallelic inactivation of genes, and time period to sacrifice after Cre activation.
Bock et al have recently described the development and advancement of mouse models for 
human cancer.45 They hierarchically cluster mouse models of cancer into five stages of 
development and sophistication. The fifth stage, largely futuristic, includes earlier stage 
models mimicking metastatic progression, with metastasis becoming rate limiting for tumor 
growth. In our opinion, the conditional NE carcinoma models fulfill these criteria, and thus 
represent one of the most advanced of the currently available mouse models for cancer.
Conclusions
In conclusion, GEMMs offer appropriate and potentially useful models for the study of the 
multistage development, invasion, metastases and therapy of the entire spectrum of human 
high-grade NE lung carcinomas. A detailed understanding of the pathology and biology of 
the individual GEMM models for NE carcinomas is essential for the selection of the most 
appropriate model for future studies.
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Fig. 1. 
SCLC tumors. A and C: Berns laboratory, (p53;Rb1 double CKO); B and D: Sage 
laboratory, (p53;Rb1;p130 triple CKO). A, whole lung section demonstrating multiple in 
situ lesions arising in large airways and a few small invasive carcinomas. Bar indicates 10 
microns. B, SCLC with area of necrosis and Azzopardi effect. C, high power view of SCLC 
morphology. D, combined SCLC carcinoma, with focal areas of poorly differentiated 
NSCLC.
The pathologies of various GEMMs are illustrated. Except where indicated. Horizontal bars 
= distance in microns as indicated.
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Fig 2. 
Metastases from SCLC. In all models examined, the metastatic tumors usually had SCLC 
morphology irrespective of the GEMM or the dominant pulmonary tumor phenotype. A and 
C: Berns laboratory, B: Sage laboratory, D: Jacks laboratory (p53; Rb1; Pten triple CKO). 
A. Extensive mediastinal spread, modest intrapulmonary tumor. B. Intrapulmonary 
perivascular lymphatic spread with focal invasion of blood vessel (BV) wall. C. Metastasis 
to mediastinal node. D. Metastases to liver.
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Fig 3. 
LCNECs. A and B: Johnson laboratory; C and D: Sage laboratory (both laboratories used 
the same p53;Rb1;p130 triple CKO). A. Intrabronchial in situ lesion with underlying 
invasive component. B. A lesion similar to the one illustrated in A, CGRP immunostain. 
Strong cytoplasmic expression of the NE cell product CGRP in both the in situ and invasive 
tumor components. C. High power view of LCNEC morphology. D. Both LCNEC (left 
field) to SCLC (right field) morphologies are present within a single lesion.
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Fig. 4. 
NSCLC tumors. A and B: Johnson laboratory; C and D MacPherson laboratory 
(p53;Rb1;PTEN triple CKO). A and B, Adjacent LCNEC (left field) and NSCLC (right 
field) tumors in the p130 triple knockout model. CGRP immunostaing (B) is limited to the 
LCNEC tumor and an adjacent neuroepithelial body in (NEB) within a bronchus separating 
the two tumors. C and D. In situ SCLC and adjacent invasive NSCLC-NE arising in a 
Ptenlox/+ triple knockout mouse. CGRP immunostaining (D) demonstrates that the NE cell 
marker expression is limited to the in situ SCLC component and to a neuroepithelial body 
(NEB) in the same bronchus.
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Fig. 5. 
Non small cell lung carcinomas with expression of NE cell markers (NSCLC-NE). A and B: 
MacPherson Laboratory; C and D Linnoila laboratory (SV40/ASCL1 driven by CC10 
promoter). A, Adenocarcinoma. B, same tumor as A immunostained for CGRP expression. 
C and D Poorly differentiated NSCLC immunostained for Cgrp (C) or Ascl1 (D). There is 
focal and variable NE marker expression in the tumor. Immunostaining of the foci of NE 
cell hyperplasia in adjacent bronchi show more intense and uniform expression of Ascl1.
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